Data from our VRON-0200 Chronic HBV program continue to show great promise towards it being a pivotal component of future HBV Functional Cure regimens. First, we showed a favorable safety and ...

专注于开发基于新型 T 细胞免疫疗法的临床阶段生物技术公司 Virion Therapeutics 近日在北京举办的2025年亚太肝病学会年会（APASL2025）上公布了旗下一款用于慢性乙型肝炎治疗的在研免疫疗法 VRON-0200 ...

面对如此积极的研究进展，慢乙肝患者及其家属都感到无比欣喜。对于这一群体而言，能够有新的治疗选择，无疑是更为重要的希望。随着后续临床数据的逐步公布，VRON-0200的应用前景将愈加明朗，有望为数以百万计的慢乙肝患者打开一扇新窗。

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...